Fortrea Holdings (FTRE) Interest Expenses (2022 - 2023)
Fortrea Holdings (FTRE) reported Interest Expenses of $34.5 million for Q4 2023, up 17150.0% on a YoY basis from N/an in Q4 2022, and little changed quarter-over-quarter from $34.6 million in Q3 2023.
Fortrea Holdings (FTRE) Interest Expenses (2022 - 2023) Analysis & Trends
Fortrea Holdings has reported Interest Expenses for 2 years, with the latest figure at $34.5 million in Q4 2023.
- For the quarter ending Q4 2023, Interest Expenses rose 17150.0% year-over-year to $34.5 million; the trailing twelve-month figure through Sep 2024 stood at $34.5 million (down 2.82% YoY), and the FY2023 full-year result was $69.8 million, up 34800.0% from the prior year.
- Interest Expenses for Q4 2023 stood at $34.5 million, roughly flat from $34.6 million in the prior quarter.
- The five-year high for Interest Expenses was $34.6 million in Q3 2023, with the low at $200000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -5.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -332,000.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 61,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -2,753.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -5.58 Mn |
| 10 | Fortrea Holdings | 1.43 Bn | 1.28 Bn | 123.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 34.50 Mn |
| Dec 31, 2023 | 34.50 Mn |
| Sep 30, 2023 | 34.60 Mn |
| Sep 30, 2023 | 34.60 Mn |
| Jun 30, 2023 | 700,000.00 |
| Jun 30, 2023 | 700,000.00 |
| Dec 31, 2022 | 200,000.00 |
| Dec 31, 2022 | 200,000.00 |